Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Simone Koole; Ruby van Stein; Karolina Sikorska; Desmond Barton; Lewis Perrin; Donal Brennan; Oliver Zivanovic; Berit Jul Mosgaard; Anna Fagotti; Pierre-Emmanuel Colombo; Gabe Sonke; W J van Driel

doi:10.1136/ijgc-2020-001231

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

other Versions

View the most recent version of this article
You are currently viewing an earlier version of this article (February 08, 2021).

Clinical trial

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Read the full text or download the PDF:

Log in using your username and password